253 related articles for article (PubMed ID: 31297968)
1. Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial.
Ledesma G; Umpierrez GE; Morley JE; Lewis-D'Agostino D; Keller A; Meinicke T; van der Walt S; von Eynatten M
Diabetes Obes Metab; 2019 Nov; 21(11):2465-2473. PubMed ID: 31297968
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged ≥ 60 Years Treated with Basal Insulin: A Randomised Trial.
Araki E; Unno Y; Tanaka Y; Sakamoto W; Miyamoto Y
Adv Ther; 2019 Oct; 36(10):2697-2711. PubMed ID: 31482511
[TBL] [Abstract][Full Text] [Related]
3. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
Guo XH; Feng ZK; Xu LH
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):588-594. PubMed ID: 28789492
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
Lajara R; Aguilar R; Hehnke U; Woerle HJ; von Eynatten M
Clin Ther; 2014 Nov; 36(11):1595-605. PubMed ID: 25236917
[TBL] [Abstract][Full Text] [Related]
5. Risk of hypoglycaemia in people aged ≥65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus.
Nauck M; Araki A; Hehnke U; Plat A; Clark D; Khunti K
Int J Clin Pract; 2018 Oct; 72(10):e13240. PubMed ID: 30216648
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.
Laffel LM; Danne T; Klingensmith GJ; Tamborlane WV; Willi S; Zeitler P; Neubacher D; Marquard J;
Lancet Diabetes Endocrinol; 2023 Mar; 11(3):169-181. PubMed ID: 36738751
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of linagliptin as add-on therapy to insulin in Chinese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial.
Yang W; Xu X; Lei T; Ma J; Li L; Shen J; Ye B; Zhu S; Meinicke T
Diabetes Obes Metab; 2021 Feb; 23(2):642-647. PubMed ID: 33074590
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Linagliptin in 2681 Asian Patients Stratified by Age, Obesity, and Renal Function: A Pooled Analysis of Randomized Clinical Trials.
Ning G; Bandgar T; Hehnke U; Lee J; Chan JCN
Adv Ther; 2017 Sep; 34(9):2150-2162. PubMed ID: 28819835
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
Han SY; Yoon SA; Han BG; Kim SG; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang Y; Kim B; Shin S; Cha DR
Diabetes Obes Metab; 2018 Feb; 20(2):292-300. PubMed ID: 28719008
[TBL] [Abstract][Full Text] [Related]
10. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.
Barnett AH; Huisman H; Jones R; von Eynatten M; Patel S; Woerle HJ
Lancet; 2013 Oct; 382(9902):1413-23. PubMed ID: 23948125
[TBL] [Abstract][Full Text] [Related]
11. Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia.
Ross SA; Caballero AE; Del Prato S; Gallwitz B; Lewis-D'Agostino D; Bailes Z; Thiemann S; Patel S; Woerle HJ; von Eynatten M
Postgrad Med; 2016 Nov; 128(8):747-754. PubMed ID: 27684308
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial.
Wang W; Yang J; Yang G; Gong Y; Patel S; Zhang C; Izumoto T; Ning G
J Diabetes; 2016 Mar; 8(2):229-37. PubMed ID: 25753488
[TBL] [Abstract][Full Text] [Related]
13. Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
McGill JB; Yki-Järvinen H; Crowe S; Woerle HJ; von Eynatten M
Diab Vasc Dis Res; 2015 Jul; 12(4):249-57. PubMed ID: 25941160
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
Zinman B; Ahrén B; Neubacher D; Patel S; Woerle HJ; Johansen OE
Can J Diabetes; 2016 Feb; 40(1):50-7. PubMed ID: 26474870
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetes.
Durán-Garcia S; Lee J; Yki-Järvinen H; Rosenstock J; Hehnke U; Thiemann S; Patel S; Woerle HJ
Diabet Med; 2016 Jul; 33(7):926-33. PubMed ID: 26605991
[TBL] [Abstract][Full Text] [Related]
16. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
[TBL] [Abstract][Full Text] [Related]
17. Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.
Bajaj M; Gilman R; Patel S; Kempthorne-Rawson J; Lewis-D'Agostino D; Woerle HJ
Diabet Med; 2014 Dec; 31(12):1505-14. PubMed ID: 24824197
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of linagliptin/metformin single-pill combination as initial therapy in drug-naïve Asian patients with type 2 diabetes.
Mu Y; Pan C; Fan B; Hehnke U; Zhang X; Zhang X; Wang X; Liu J; Zhang Y; Du J; Ma J; Gong Y
Diabetes Res Clin Pract; 2017 Feb; 124():48-56. PubMed ID: 28088030
[TBL] [Abstract][Full Text] [Related]
19. Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes.
Inzucchi SE; Nauck MA; Hehnke U; Woerle HJ; von Eynatten M; Henry RR
Diabetes Obes Metab; 2015 Sep; 17(9):868-77. PubMed ID: 25974030
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA).
Christensen AS; Hædersdal S; Støy J; Storgaard H; Kampmann U; Forman JL; Seghieri M; Holst JJ; Hansen T; Knop FK; Vilsbøll T
Diabetes Care; 2020 Sep; 43(9):2025-2033. PubMed ID: 32661107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
